Thymoma future or investigational therapies
Medi
|
Thymoma Microchapters |
|
Diagnosis |
|---|
|
Case Studies |
|
Thymoma future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Thymoma future or investigational therapies |
|
Risk calculators and risk factors for Thymoma future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Amr Marawan, M.D. [2]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Due to the advancement in understanding the molecular biology of the disease, there is an increased number of targeted therapies being tested in clinical trials, but the results have so far been disappointing.
Targeted Therapy
- KIT pathway
It is overexpressed by immunohistochemistry in 2% of thymomas and in 79%of thymic carcinomas. Imatinib and nilotinib are been tried in several clinical trials.[1]
- Epidermal growth factor pathway
It is overexpressed by immunohistochemistry in 70% of thymomas and in 53%of thymic carcinomas. Cetuximab, erlotinib, gefitinib are being used in diff clinical trials.[2]
- IGF-1R pathway
Expression of IGF-1R was found in 4% of thymomas and in 37% of thymic carcinomas. Figitumumab and cixutumumab have been tried in ndifferent clinical trials.[3]